Bactroban Shortage: What Providers and Prescribers Need to Know in 2026

Mupirocin (Bactroban) remains the first-line topical antibiotic for impetigo and secondarily infected skin lesions in U.S. clinical guidelines. While there is no active FDA-declared national shortage as of 2026, several converging factors are causing prescribers to rethink their standard mupirocin protocol: increasing resistance, formulary limitations, and periodic local availability gaps that leave patients without treatment.

This guide provides an up-to-date clinical summary for primary care physicians, pediatricians, dermatologists, urgent care providers, and NPs/PAs who routinely prescribe mupirocin.

Current Availability Status (2026)

As of 2026, the FDA Drug Shortages database does not list mupirocin as a shortage product. Multiple generic manufacturers produce mupirocin 2% ointment and cream, providing reasonable supply redundancy. Bulk availability at national distributors (AmerisourceBergen, McKesson, Cardinal Health) is generally stable.

However, localized stockouts do occur — particularly at independent pharmacies, in rural areas with fewer pharmacy options, and during peak impetigo season (late summer/early fall). Patients may call your office after being told their prescription can't be filled, which creates additional clinical touchpoints for your staff.

The Growing Concern: Mupirocin Resistance

Perhaps more consequential than supply chain issues is the rising prevalence of mupirocin resistance — particularly in MRSA strains. There are two clinically relevant resistance phenotypes:

Low-level resistance (MIC 8–256 mg/L): Mediated by chromosomal mutations; may still respond to topical mupirocin at therapeutic skin concentrations

High-level resistance (MupA gene, MIC >512 mg/L): Plasmid-mediated; mupirocin will not be effective; switch to an alternative is required

If a patient's impetigo or MRSA nasal decolonization is not responding to mupirocin after 3–5 days, consider sending a wound culture with mupirocin susceptibility testing rather than simply extending the treatment course. The overuse of mupirocin — which is increasingly common given its perceived safety profile — is a major driver of the resistance trend.

Prescribing Considerations in 2026

When prescribing mupirocin, clinical pearls to keep in mind:

Generic first. Write for "mupirocin 2% ointment" or "mupirocin 2% cream" rather than "Bactroban" unless brand is specifically required. Generic is therapeutically equivalent, widely available, and typically cheaper for patients.

Specify the correct formulation. Ointment is FDA-approved for impetigo; cream is approved for secondarily infected traumatic lesions. Nasal ointment (Bactroban Nasal, 2% mupirocin calcium) is a separate formulation not interchangeable with topical products.

Limit duration. Avoid prescribing mupirocin for longer than 10 days for topical infections unless clinically indicated. Extended use promotes resistance and increases risk of C. difficile colonization (theoretical risk) and fungal overgrowth.

Do not use mupirocin ointment in burn patients. Polyethylene glycol (PEG), the ointment vehicle, can be systemically absorbed through open wounds and is potentially nephrotoxic in large quantities.

Preferred Alternatives When Mupirocin Is Unavailable or Inappropriate

When mupirocin cannot be used or is unavailable, consider the following options based on clinical scenario:

Retapamulin 1% ointment (Altabax): FDA-approved for impetigo due to MSSA and S. pyogenes. Applied twice daily for 5 days. No cross-resistance with mupirocin. Not active against MRSA.

Ozenoxacin 1% cream (Xepi): Newer option for impetigo including mupirocin-resistant cases. Applied twice daily for 5 days; approved ages 2 months and older.

Oral cephalexin: For extensive, bullous, or widespread impetigo. Clinical trials show comparable cure rates to topical mupirocin in limited disease.

Oral clindamycin: Preferred when CA-MRSA is clinically suspected. Check local antibiogram for inducible clindamycin resistance.

How to Help Patients Find Mupirocin When It's Out of Stock

When patients call your office saying their pharmacy is out of mupirocin, you can direct them to medfinder for providers. medfinder calls pharmacies near the patient to identify which ones have the medication in stock and texts the results directly to the patient. This can reduce inbound calls to your practice from patients asking for alternative prescriptions due to stock issues.

Clinical Bottom Line for Providers

No national shortage in 2026 — but local gaps occur seasonally

Prescribe generic mupirocin by default; avoid brand-only prescribing unless necessary

Escalating mupirocin resistance (especially MupA in MRSA) warrants culture-guided therapy when treatment fails

Retapamulin, ozenoxacin, and oral cephalexin are viable alternatives based on clinical scenario

Direct patients to medfinder when stock issues arise to reduce unnecessary office callbacks